Related Experiment Video
Updated: Aug 27, 2025
06:15
Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma
Published on: October 27, 2014
27.5K
Treatments against Polymorphosal discrepancies in Glioblastoma Multiforme
Nobendu Mukerjee1,2, Swastika Maitra3, Subhradeep Roy4
1Department of Microbiology, Ramakrishna Mission Vivekananda Centenary College, Rahara, Khardah, West Bengal, Kolkata, 700118, India. nabendu21@rkmvccrahara.org.
Metabolic Brain Disease
|September 23, 2022
Summary
This study identifies frequent single nucleotide polymorphisms (SNPs) linked to glioblastoma (GB) development. Understanding these genetic variations is crucial for diagnosing and treating this aggressive brain cancer.
Area of Science:
- Neuro-oncology
- Cancer Genetics
- Molecular Biology
Background:
- Glioblastoma (GB) is an aggressive brain tumor causing increased intracranial pressure and neurological deficits.
- GB can lead to vascular complications like thrombi and endothelial damage.
- Single nucleotide polymorphisms (SNPs) are increasingly recognized for their role in cancer development and progression.
Purpose of the Study:
- To compile a comprehensive list of significant single nucleotide polymorphisms (SNPs) associated with glioblastoma (GB).
- To highlight the role of genetic variations, particularly in promoter regions, in polygenetic susceptibility to glioma.
Main Methods:
- Literature review and data compilation of identified SNPs.
- Analysis of SNP frequency and significance in glioblastoma patient cohorts.
- Focus on SNPs located in gene promoter regions.
Main Results:
- Several frequent and significant SNPs have been identified and associated with GB formation.
- A high abundance of specific SNPs in promoter regions contributes to polygenetic vulnerability.
- These genetic markers are implicated in both the initiation and proliferation of glioblastoma.
Conclusions:
- Single nucleotide polymorphisms (SNPs) play a critical role in the pathogenesis of glioblastoma.
- Identifying these genetic variations can improve our understanding of GB risk and progression.
- Further research into these SNPs may offer novel therapeutic targets.
